All products sold on this website are for Research Use Only (RUO). Not for human or veterinary use. Not approved by the FDA for any therapeutic purpose.

>99% Purity | Same-Day Shipping | 24/7 Research Support | Free Shipping $200+

0

Product

P-TR10

GLP2 – Tirz

4.8

(407)

Tirzepatide is a dual glp-1 and gip receptor agonist peptide developed for research into metabolic regulation. Research applications include investigations into glucose homeostasis, insulin secretion, weight management, appetite control, and metabolic syndrome in experimental models.
1 Bottle
$59.00
2 Bottles
$56.05 (5% off)
3+ Bottles
$54.58 (7% off)
Quantity
x

15 Apl Wed - 18 Apl Wed

Free shipping protection

Overnight shipping available

We accept

Free Shipping

On Orders over $200

100% Damage

Protection

Secure Checkout

For you Everytime you purchase

Frequently Researched Together

Products commonly paired with Retatrutide for complementary research applications

Tesamorelin

Price range: $89.00 through $175.00

4.9

(310)

KLOW (TB + BPC-157 + GHK + KPV)

Original price was: $194.00.Current price is: $159.00.

4.9

(417)

BPC-157 + TB-500

$109.00

4.9

(233)

MOTS-C

Price range: $49.00 through $155.00

4.9

(238)

COA Documentation

Every batch includes an in-depth Certificate of Analysis with full HPLC chromatograms, mass spectrometry profiles, synthesis records, and validated purity results to ensure total transparency.

Latest

99.8 %

PURITY

Variant

Tirzepatide 20 mg

Lot #

TR20-2603-02

Labeled

20 mg

Actual

21 mg

Tested

3/30/2026

Compound Informations

Chemical and structural properties

What Is GLP2 - Tirz? MOLECULAR PROFILE

What Is GLP2 - Tirz?

Essential dinucleotide coenzyme

Synthetic GIP/GLP-1 Agonist
CAS Number 2023788-19-2
Molecular Weight 4,813 g/mol
Amino Acids 39
Fatty Acid Chain C20 diacid
Stability Information STORAGE REQUIREMENTS

Stability Information

Avoid freeze/thaw cycles Protect from light Keep refrigerated
❄️ Lyophilized (powder) -20°C • 24+ months
💉 Reconstituted 2-8°C • ~30 days

Sources & References

Peer reviewed research

NEW ENGLAND JOURNAL OF MEDICINE

Tirzepatide once weekly for the treatment of obesity

2022 • DOI: 10.1056/NEJMoa2206038 Jastreboff AM, et al.

View Source
PUBMED CENTRAL

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

2021 • SURPASS-2 Trial Data Frías JP, et al.

View Source
CLINICALTRIALS.GOV

Ongoing Clinical Evaluations of Tirzepatide (SURMOUNT/SURPASS)

2026 • Phase III Clinical Data Repository NCT Clinical Database

View Source
FDA DRUG DATABASE

Prescribing Information & Technical Summary

2026 • Regulatory Standards for Tirzepatide Official FDA Reference

View Source

IMPORTANT RESEARCH NOTICE

Not for Human Consumption

This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

all clinical trial data and research findings presented on this page are sourced from Peer- Reviewed journals and official publications. They are provided for educational reference only ans should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulatios.

0

Age Verification Required

You must be 21 years or older to access this website.

You must be 21 years or older to access this website. By continuing, you confirm that you are of legal age and are purchasing these products strictly for laboratory research purposes only. These products are not for human or veterinary use.

I confirm I am 21 years or older
I am purchasing strictly for laboratory research purposes only
I understand these products are not for human or veterinary use